Best Immunotherapy Companies in United Kingdom
The 129 best Immunotherapy companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kymab.
Ranking the top Immunotherapy companies in the United Kingdom by disclosed equity funding, this directory tracks 129 ventures that have collectively pulled in $3.4B. That's the number to hold. The global immunotherapy market sat at $13.8B in 2021 and is growing at a 13.8% CAGR, driven by rising autoimmune disease prevalence and accelerating cancer research investment. So when you see that kind of clip globally, the UK cohort's funding density starts to make sense.
Enara Bio leads our tracked set at $84M, with Cytospire Therapeutics close behind at $83M and Centauri Therapeutics at $65M. T-Therapeutics has disclosed $59M, Iksuda Therapeutics $50M. No unicorns yet, but the pipeline momentum is real, and hot themes like checkpoint inhibitors and cancer vaccines are pulling serious institutional attention, as recent clinical work on combination approaches continues to expand the therapeutic surface area. Government bodies and UKRI are the most active backers here, alongside IP Group, Medicxi, and Oxford Science Enterprises. I'd note that government-heavy cap tables often signal regulatory sensitivity, and strict policy frameworks in certain regions do shape how fast these programs can advance.
- ResearchAndMarkets.com
- The Business Research Company
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kymab Provider of monoclonal antibody therapeutics for multiple diseases | $348M | 83 mo ago | 183 | Allan Bradley Founder & Director | — | — | 872 patents Immunotherapy antibodies targeting immune checkpoints and co‑stimulatory receptors | — |
| 2 | Quell Developer of engineered regulatory T cell therapies for immune diseases | $344M | 41 mo ago | 18 | Giovanna Lombardi Co-Founder | TurbopackNode.jsSalesforce+13 | — | — | 1 partnership |
| 3 | Achilles Therapeutics Developer of T-cell therapies for cancer | $242M | 47 mo ago | 118 | Charles Swanton Co-Founder | NginxAzureGoogle Font API+2 | — | 56 patents Neoantigen discovery and peptide synthesis for personalized cancer immunotherapy | — |
| 4 | Pheon Therapeutics Developer of antibody drug conjugates for treating solid tumor cancers | $188M | 25 mo ago | 8 | Bertrand Damour CEO | — | — | 37 patents Targeted antibody‑drug conjugates and novel cytotoxic small‑molecule therapeutics. | — |
| 5 | Autolus Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 28 mo ago | 51 | Martin Pule Founder | Apple iCloud MailMicrosoft 365GSAP+17 | 4 signals ▼50% Earnings | 648 patents Patents concentrated in chemistry & materials | 1 award |
| 6 | Crescendo Biotechnology company developing antibody-based cancer immunotherapies and targeted biologic treatments | $141M | 34 mo ago | 43 | Theodora Harold CEO | — | — | — | — |
| 7 | Mereo BioPharma Developer of therapeutics for cancer and rare diseases | $141M | 72 mo ago | 56 56 → 45 (-20%) · sector median +46% | Charles Sermon Co-Founder | Apple iCloud MailMicrosoft 365Azure+8 | 6 signals ▲20% Lawsuit · Earnings | 273 patents Anti‑sclerostin antibodies for osteogenesis imperfecta and neutrophil elastase inhibitors for respiratory disease | — |
| 8 | MiroBio Developer of therapeutics for auto-immune diseases | $132M | 48 mo ago | 29 | Simon Davis Co-Founder | — | — | 69 patents Therapeutic antibodies targeting BTLA and CD200R immune checkpoint proteins. | — |
| 9 | Myricx Bio Developer of antibody drug conjugates for the treatment of cancer | $121M | 23 mo ago | 6 | Robin Carr CEO | WordPressMySQLPHP+10 | — | — | — |
| 10 | Vicebio Developer of vaccines to treat viral infectious diseases 35Growth top 15%Funding top 26%News top 26%Moat top 47% All 9 signals ▾Growthtop 15% Fundingtop 26% Newstop 26% Moattop 47% Talentbottom 49% Globalbottom 37% Patentsbottom 35% Marketbottom 25% Innovationbottom 22% Growth: Fresh capital in last 24 mo Funding: Raised $100M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $100M | 20 mo ago | 4 | Emmanuel Hanon CEO | — | 6 signals ▲500% M&A | 2 patents Recombinant chimeric fusion protein vaccines for hMPV and RSV respiratory viruses | — |
| 11 | NodThera Developer of therapeutics for treating inflammatory and neuroinflammatory diseases | $95M | 72 mo ago | 19 19 → 27 (+42%) · sector median +46% | Alan Watt CEO | — | — | 140 patents Synthesis of heterocyclic carbamate/urea compounds for inflammasome‑targeted drugs | — |
| 12 | Allergy Therapeutics Developer of treatments for allergy and immune related disorders | $94M | 95 mo ago | 601 601 → 380 (-37%) · sector median +46% | — | Apple iCloud MailMicrosoft 365Microsoft ASP.NET+8 | 4 signals Earnings · Funding | 45 patents Allergen-specific immunotherapy vaccines for food allergy treatment | — |
| 13 | Replimune Developer of oncolytic immunotherapies | $87M | 105 mo ago | 152 152 → 362 (+138%) · sector median +46% | Philip Astley-Sparke Co-Founder | WordPressDrupalApple iCloud Mail+24 | 8 signals Earnings · Layoffs · Regulatory | 92 patents Engineered oncolytic viruses for cancer immunotherapy and targeted gene delivery | — |
| 14 | Enara Bio Developer of T-cell based cancer-cell interface for therapeutics | $84M | 20 mo ago | 38 38 → 68 (+79%) · sector median +46% | Kevin Pojasek CEO & President | RubyAnimate.cssVarnish+13 | — | 63 patents Bispecific polypeptide therapeutics targeting novel cancer antigens for immunotherapy | — |
| 15 | Cytospire Therapeutics Provider of immune cell engagers for treating cancer 53Funding top 24%Global top 45%Talent bottom 49% All 3 signals ▾Fundingtop 24% Globaltop 45% Talentbottom 49% Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 4 countries beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | — | Natalie Mount CEO | — | — | — | 1 award |
| 16 | Centauri Therapeutics Developer of immunotherapeutics to treat infectious diseases 35Funding top 26%Growth top 35%Moat top 36%Patents top 46% All 9 signals ▾Fundingtop 26% Growthtop 35% Moattop 36% Patentstop 46% Talentbottom 49% Innovationbottom 42% Globalbottom 42% Techbottom 41% Marketbottom 25% Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $65M | 3 mo ago | 6 | Jennifer Schneider CEO | WordPress Block EditorWordPressMySQL+15 | — | 50 patents Patents concentrated in chemistry & materials | — |
| 17 | Prokarium Developer of bacterial immunotherapy treatments for various types of cancer | $62M | 41 mo ago | 20 20 → 17 (-15%) · sector median +46% | Ibraheem Mahmood CEO | — | — | 77 patents Patents concentrated in health & consumer products | — |
| 18 | T-Therapeutics Developer of T-cell-based rtherapeutics for cancer treatment 62Patents top 12%Innovation top 19%Moat top 26%News top 27% All 10 signals ▾Patentstop 12% Innovationtop 19% Moattop 26% Newstop 27% Fundingtop 30% Growthtop 32% Talenttop 38% Techbottom 47% Globalbottom 45% Marketbottom 32% Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $59M | 7 mo ago | — | Haydn Prosser Co-Founder & Director | WordPressMySQLPHP+21 | 5 signals Funding | 239 patents Therapeutic nucleic acid agents for gene expression inhibition (antisense, siRNA, oligonucleotide conjugates). | 1 job opening |
| 19 | VHsquared Designs and develops antibodies engineered to be stable in the gastrointestinal (GI) tract. | $58M | 59 mo ago | 8 | Rod Richards CEO | — | — | 62 patents Design and synthesis of therapeutic peptides and protease‑cleavable peptide drug conjugates | — |
| 20 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 65 mo ago | 9 | Vicente Gonzalez Co-Founder | — | — | — | — |
| 21 | Epsilogen Developer of immunoglobulinE antibodies for the treatment of cancer | $54M | 21 mo ago | 4 | Tim Wilson CEO at Epsilogen Ltd | WordPressMySQLPHP+17 | — | 19 patents Engineered therapeutic antibodies, especially IgE and hybrid formats targeting HER2 low-expression cancers | — |
| 22 | Iksuda Therapeutics Developer of antibody drug conjugates for the treatment of solid cancers | $50M | 14 mo ago | 16 | David Simpson Co-Founder & CEO | GSAPAzureMicrosoft Advertising+12 | — | 29 patents Design and formulation of antibody‑drug conjugates and their linkers for targeted therapy. | — |
| 23 | Epitopea Developer of immunotherapeutics for the treatment of cancer | $45M | 19 mo ago | 10 | Jon Moore CEO | WordPressPleskMySQL+17 | — | — | — |
| 24 | C4X Discovery Developer of optimized drug discovery and design services | $43M | 29 mo ago | 46 | — | WordPressMySQLPHP+15 | — | 130 patents Small‑molecule inhibitors of MALT1, NRF2 agonists, and integrin blockers for immuno‑inflammatory therapy | — |
| 25 | SpyBiotech Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology | $39M | 39 mo ago | 10 10 → 20 (+100%) · sector median +46% | Simon Draper Co-Founder | WordPressSentryMySQL+19 | — | 29 patents Engineering adenoviral vectors and capsid-modified viral vaccines for immunization | — |
| 26 | Adaptate Biotherapeutics Developer of T-cell based immunotherapy for treating cancer | $34M | 62 mo ago | 21 | — | — | — | 4 patents Engineered antibodies targeting TCR delta variable 1 for immunotherapy | — |
| 27 | PrEP Biopharm Developing RNA based immunomodulators for the prevention of respiratory infections | $32M | 127 mo ago | 118 | — | — | — | — | — |
| 28 | Emergex Vaccines Developer T-cell Vaccines for treating viral and bacterial infections | $30M | 51 mo ago | 19 | Storme Moore-Thornicroft Co-Founder | — | — | 89 patents Peptide-based vaccines and MHC I epitope therapeutics for coronaviruses and flaviviruses | — |
| 29 | Glide Technologies Specialty company developing drug delivery products | $29M | 112 mo ago | 22 | — | — | — | — | — |
| 30 | TC Biopharm Developer of T-cell therapies for cancer and infectious disease treatment | $28M | 42 mo ago | 79 | — | — | — | 52 patents Patents concentrated in chemistry & materials | — |
| 31 | Tiziana Life Sciences Developer of small-molecule drugs for cancer and autoimmune diseases | $22M | 79 mo ago | 11 | — | DrupalPHPZURB Foundation+20 | — | 79 patents Patents concentrated in chemistry & materials | — |
| 32 | Treos Bio Developer of cancer vaccines and companion diagnostics | $22M | 62 mo ago | 12 12 → 16 (+33%) · sector median +46% | — | — | — | 65 patents Personalized peptide-based cancer vaccines and immunogenic peptide discovery platforms | — |
| 33 | Leucid Bio Developer of therapeutics for the treatment of cancers | $22M | 59 mo ago | 10 10 → 23 (+130%) · sector median +46% | John Maher Co-Founder | WixSentryBootstrap+10 | — | — | — |
| 34 | Valink Therapeutics Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases | $20M | 8 mo ago | — | Irsyad Khairil Co-Founder & CTO | WebflowApple iCloud MailMicrosoft 365+10 | — | — | — |
| 35 | Biosceptre Develops immunotherapies for oncology | $16M | 102 mo ago | 10 10 → 15 (+50%) · sector median +46% | — | — | — | 28 patents Engineering chimeric antigen receptors and cytotoxic particle therapeutics for targeted immunotherapy | — |
| 36 | Maxion Therapeutics Developer of antibody-based drugs to treat multiple diseases | $16M | 15 mo ago | 4 | Aneesh Vellatt Co-Founder & CSO | WebflowjQueryHSTS+8 | — | — | 1 job opening |
| 37 | Mtem Developer of next-gen immunotoxins for cancer | $14M | 34 mo ago | 222 | — | — | — | 130 patents Marine electromagnetic subsurface surveying and resistivity measurement for underwater formation analysis | — |
| 38 | Etcembly Developer of AI-driven technology for engineering and designing novel immunotherapies | $13M | 36 mo ago | — | Jacob Hurst Co-Founder & CTO | Wix eCommerceWixSentry+19 | — | — | — |
| 39 | OVM Therapeutic peptide vaccines for cancer | $12M | 19 mo ago | 5 | Shisong Jiang Founder & Director | — | — | — | — |
| 40 | Macomics Developer of immnotherapies for treating cancer | $10M | 58 mo ago | 2 | Jeffrey Pollard Co-Founder | — | — | 13 patents Gene editing vectors and macrophage-modulating therapeutics for cancer diagnostics and treatment. | — |
| 41 | ILC Therapeutics Developer of immunotherapeutics for the treatment cancer | $8M | 21 mo ago | 2 | Bill Stimson Founder | — | — | 51 patents Patents concentrated in chemistry & materials | — |
| 42 | DJS Antibodies Developer of antibody therapeutics for inflammatory conditions | $8M | 28 mo ago | 16 | Robert Michael CEO | — | — | 12 patents Therapeutic antibody polypeptide design and production technologies | — |
| 43 | NK:IO Developer of small molecule therapies for hematological and solid tumors | $7M | 18 mo ago | 1 | Matthew Fuchter Co-Founder | — | — | — | — |
| 44 | Scancell Biotechnology company developing immunotherapies for cancer treatment | $6M | 18 mo ago | 22 | Phil Huillier CEO | WordPressMySQLPHP+21 | — | 167 patents Glycoengineered therapeutic antibodies and vaccine antigens targeting fucosylated cancer markers | 1 award |
| 45 | Athernal Bio Developer of vaccines to target and lower the risk of cancer and other age-related diseases | $5M | 8 mo ago | — | Nirupa Desai Co-Founder | Framer SitesReactPriority Hints+6 | — | — | — |
| 46 | Evariste AI-based drug discovery platform to target synthetic lethal pathways in oncology | $4M | 33 mo ago | 9 | Anna Hercot CEO | Webflow EcommerceWebflowCloudflare Turnstile+11 | — | — | — |
| 47 | BiVictriX Therapeutics Developer of bi-specific antibody-drug conjugates for the treatment of cancer | $2M | 24 mo ago | 4 | — | WordPressMySQLPHP+13 | — | — | — |
| 48 | Siftr Bio Developer of antibofy drug conjugates for cancer treatment | $1M | 18 mo ago | — | Ed Tate Co-Founder | — | — | — | — |
| 49 | Bastion Therapeutics Developer of cell therapy for inflammatory disorders and autoimmune diseases | $1M | 28 mo ago | — | Nia Emami Co-Founder & CSO | — | — | — | — |
| 50 | Lentitek Developer of technology to enhance lentiviral vector quality and yield | $309K | 15 mo ago | 3 | Leif Anderson Co-Founder | — | — | 3 patents Design and production of genetic expression vectors for recombinant protein synthesis. | — |
Top 12 Immunotherapy companies in United Kingdom
#1
Series A · London, England · founded 2023$83Mraised▾
Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.
- May 2026Series A$83M
- Seed—
#2
Series A · Kent, England · founded 2014 · 6 employees$64.9Mraised▾
Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.
- Feb 2026Series A$8.1M
- Jul 2025Grant (prize money)$5.1M
- Nov 2024Grant (prize money)$1.3M
- Jul 2023Series A$11.5M
#3
Series A · Cambridge, England · founded 2022$59.4Mraised▾
Developer of T-cell-based rtherapeutics for cancer treatment. It offers T-cell receptor-based drugs that recognise specific cancers and patient’s own T cells to kill the cancer cells and eradicate the tumour.
- Nov 2025Series A$32M
- Nov 2023Series A$59.4M
#4
Seed · London, England · founded 2020$19.6Mraised▾
Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases. The company focuses on creating more effective drugs that differentiate between diseased and healthy cells. It utilizes a discovery engine built on synthetic protein biology, high-throughput functional screening, and artificial intelligence. The company is advancing oncology-focused programs.
- Oct 2025Seed$11.8M
- Nov 2023Seed$7.8M
#5
Series A · Newcastle Upon Tyne, England · founded 2012 · 16 employees$49.6Mraised▾
Developer of antibody-drug conjugates for the treatment of solid cancers including ovarian, lung, pancreas, cervix, and renal cell carcinoma. The company's product pipeline includes IKS01 which is in pre-clinical trials, IKS02, IKS03, IKS04 which are in the discovery phase.
- Mar 2025Series A$15M
- Jun 2021Series A$47M
- Jun 2012Seed$2.6M
#6
Series B · Oxford, England · founded 2016 · 38 employees$84.1Mraised▾
Enara Bio is developing a T-cell based cancer-cell interface for therapeutics. The company is involved in the immune interface for cancer biology to develop and characterize immunotherapy targets, like dark antigens derived from the genomic dark matter or antigens presented by the cancer-specific MR1 receptor. The company offers proprietary TCR-directed T-cell therapies to target tumor homogeneity and cancer vaccines to generate polyclonal autologous ex vivo stimulation of T-cell products.
- Oct 2024Series B$32.5M
- May 2021Series A$16.3M
- Nov 2019Series A$17.5M
- Apr 2018Seed$7.8M
#7
Acquired · London, England · founded 2019 · 4 employees$100Mraised▾
Developer of vaccines to treat viral infectious diseases. The company has Molecular Clamp technology for high yield production of viral fusion proteins in native trimeric “prefusion” form. The lead candidate of the company includes VXB-211 which targets respiratory syncytial virus (RSV). The company has developed a pipeline for Metapneumovirus, influenza, and SARS-CoV-2.
- Sep 2024Series B$100M
#8
Series A · London, England · founded 2019 · 6 employees$120.6Mraised▾
Developer of antibody drug conjugates for the treatment of cancer. The company focuses on the development of a pipeline of proprietary differentiated antibody drug conjugates based on novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.
- Jul 2024Series A$114M
- Oct 2019Seed$6.6M
#9
Series B · London, England · founded 2016 · 4 employees$53.8Mraised▾
Developer of immunoglobulin antibodies for the treatment of cancer. It offers antibodies that help in the treatment of solid tumors. The lead product candidate, MOv18 IgE is for folate receptor alpha positive cancer patients. Other products include EPS 201 for breast cancer and gastric problems.
- Sep 2024Series B$16.4M
- Mar 2022Series B$41.1M
- Oct 2020Grant (prize money)—
- Jul 2020Grant (prize money)$627.7K
#10
Series A · Babraham, England · founded 2024$4.7Mraised▾
Developer of vaccines to target and lower the risk of cancer and other age-related diseases. The company is developing immunotherapies for high-risk clonal haematopoiesis addressing blood cancer precursor condition with the aim of stopping cancer before it starts through early and proactive therapeutic intervention.
- Oct 2025Series A$4.7M
#11
Seed · Cambridge, England · founded 2021 · 10 employees$44.6Mraised▾
Developer of immunotherapeutics for the treatment of cancer. The company's proprietary technology provides an approach to identify tumor-specific antigens, known as Cryptigens to create transformational immunotherapies including therapeutic vaccines, cell therapies, and TCR-based biologics that target broad cancer patient populations in both solid and hematological cancers.
- Oct 2024Seed$31M
- Sep 2024Grant (prize money)$658K
- Apr 2022Seed$13.6M
#12
Series A · Cambridge, England · founded 2020 · 4 employees$16Mraised▾
Developer of antibody-based drugs to treat multiple diseases. The company leverages a proprietary KnotBody technology that combines the power of Knottin evolution in targeting ion channels and GPCRs with state-of-the-art antibody engineering techniques to address autoimmunity, chronic pain, and cardiovascular diseases.
- Mar 2025Series A$72M
- Apr 2023Grant (prize money)$2.5M
- Feb 2023Series A$16M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in the United Kingdom
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,134 United Kingdom-affiliated papers.
- King's College London135
- University College London124
- Imperial College London113
- University of Oxford77
- Institute of Cancer Research77
- Immune system11→169
- Cancer2→57
- Tumor microenvironment5→52
- Cancer immunotherapy4→51
- Cancer research14→46
- Immune system18→327
- Cancer8→120
- Oncology4→99
- Internal medicine7→102
- Pembrolizumab3→71
- Immune system11→118
- Cancer10→71
- Disease2→59
- Clinical trial1→39
- Internal medicine2→39
Where immunology is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in the United Kingdom
United Kingdom immunology patent filing is cooling — 496 filings from 397 assignees (2016–2025), led by 4D Pharma RES, Snipr TECH, UNIV Birmingham; annual filings 48→33.
- 4D Pharma RES95
- Snipr TECH60
- UNIV Birmingham48
- Cambridge Entpr41
- Cancer REC TECH25
- Oxxon Therapeutics23
- Kymab23
- UNIV Oxford Innovation21
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.